Semaglutide Canada

What Is the Semaglutide Peptide?

The semaglutide peptide is a GLP-1 receptor agonist — a 31-amino-acid synthetic analog of glucagon-like peptide-1, the endogenous incretin hormone released by the gut after a meal.

Native GLP-1 has a half-life of roughly two minutes. It is destroyed almost immediately by the enzyme DPP-4, which is why it was useless as a drug for decades despite everyone understanding what it did. Semaglutide solves that with a C18 fatty diacid chain that binds reversibly to albumin, the most abundant protein in blood plasma. Bound to albumin, the peptide is shielded from degradation and cleared far more slowly — extending the half-life from two minutes to roughly 168 hours. Seven days. That single modification is what makes weekly administration possible, and the entire GLP-1 category rests on it.

Semaglutide acts exclusively at the GLP-1 receptor. It has no meaningful activity at the GIP or glucagon receptors, which separates it from the dual agonist tirzepatide and the triple agonist retatrutide.

That specificity has a practical consequence for research: semaglutide is the clean comparator. Any study isolating GLP-1 pathway effects — unconfounded by GIP or glucagon co-activation — needs a mono-agonist, and semaglutide is the best-characterised one in existence.

Is Semaglutide Legal in Canada? Approved Products and Regulatory Status

Semaglutide is an approved prescription drug in Canada. Health Canada has authorized it under three brand names, each carrying a Drug Identification Number:

• Ozempic — injection, type 2 diabetes
• Wegovy — injection, chronic weight management
• Rybelsus — oral tablets, type 2 diabetes

Generic Semaglutide Canada Approvals

Health Canada has additionally authorized generic semaglutide, becoming the first G7 regulator to do so, with further submissions under review.

Anyone seeking semaglutide as a medication should obtain an authorized, DIN-bearing product on prescription from a licensed pharmacy. That is the correct route, and it is not the route CompoundPlug serves.

Research-grade semaglutide is not an authorized product. It carries no DIN and is not pharmaceutically equivalent to Ozempic, Wegovy, Rybelsus, or any approved generic. Semaglutide is not a controlled substance. CompoundPlug supplies it strictly as a research chemical for in-vitro and in-vivo laboratory research. See Research Use Only.

Semaglutide Benefits: What the Research Reports

Weight management

The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) randomised 1,961 adults with overweight or obesity to weekly subcutaneous semaglutide 2.4 mg or placebo over 68 weeks. Mean body-weight reduction was 14.9% versus 2.4% on placebo. 86.4% of participants on semaglutide achieved at least 5% weight loss, against 31.5% on placebo.

In STEP 2, in participants who also had type 2 diabetes, mean reduction was 9.6% versus 3.4% — a smaller effect, seen consistently across this drug class in diabetic populations.

Glycemic control

The SUSTAIN programme established semaglutide’s effects on HbA1c in type 2 diabetes, and is the basis of the Ozempic indication.

Cardiovascular outcomes

The SELECT trial examined major adverse cardiovascular events in participants with established cardiovascular disease and obesity, without diabetes. This is a different class of evidence from weight reduction — a hard cardiovascular outcome rather than a metabolic surrogate — and it is the deepest part of semaglutide’s record. Nothing else in this catalog has anything comparable.

Mechanism

The reported effects are attributed to three actions: delayed gastric emptying, glucose-dependent insulinotropic action (insulin release that scales with blood glucose rather than firing regardless — which is why hypoglycemia risk is lower than with older agents), and central appetite suppression via GLP-1 receptors in the hypothalamus and brainstem.

Semaglutide Dosage in the Published Research

Semaglutide is unusual in this catalog: its dosing literature is human clinical trial data, not animal data. Tens of thousands of participants across a decade of trials.

Injectable — SUSTAIN and STEP

SUSTAIN (type 2 diabetes) evaluated weekly subcutaneous doses of 0.5 mg to 1.0 mg, with later work extending to 2.0 mg.

STEP (chronic weight management) evaluated weekly doses up to 2.4 mg, reached across a 16-week escalation period — a design chosen to manage gastrointestinal tolerability, which is the dose-limiting factor for this entire drug class.

Oral — PIONEER

Oral semaglutide evaluated daily doses of 3 mg to 14 mg. The order-of-magnitude difference from the injectable doses reflects the very low oral bioavailability of a peptide this size — most of an oral dose never reaches circulation.

What these figures are

These are trial parameters. Where semaglutide is prescribed as an authorized product, the dose is set by a physician, individualized, and documented in the product monograph. It is not determined by a supplier, a website, or a calculator.

CompoundPlug provides no dosing recommendations. The Peptide Calculator converts vial mass and diluent volume into a concentration and draw volume — the mass is an input supplied by the researcher.

Semaglutide Side Effects Reported in Studies

Gastrointestinal — the dominant finding

Nausea, vomiting, and diarrhea are the most frequently reported adverse events across the trial programme, and they are dose-related. This is not incidental — it is the reason every protocol escalated gradually rather than starting at target. In STEP 1, most gastrointestinal events were transient and mild to moderate.

Documented risks

Health Canada documents the known risks associated with authorized GLP-1 products: severe gastrointestinal problems, pancreatitis, worsening kidney injury, and hypoglycemia — the last particularly in combination with other medications.

The distinction that matters

Every effect above was observed with authorized, GMP-manufactured pharmaceutical semaglutide: a known quantity of a known molecule. A vial containing the wrong amount of the right compound, or the right amount of the wrong compound, has no safety profile at all.

Semaglutide Half-Life & Pharmacokinetics

Semaglutide’s pharmacokinetics are among the best-characterised of any peptide in existence, because it went through full clinical development.

• Half-life: approximately 168 hours — seven days. The design goal, achieved through albumin binding.
• Native GLP-1: approximately two minutes. The comparison is the whole story. Semaglutide extends the half-life of its parent molecule by a factor of roughly five thousand.
• Mechanism: the C18 fatty diacid chain binds albumin reversibly. Bound peptide is protected from DPP-4 degradation and renal clearance; free peptide is released slowly as the bound fraction re-equilibrates.
• Steady state is reached after roughly four to five weeks of weekly administration — which is why escalation protocols run over a comparable period rather than adjusting week to week.
• Oral bioavailability is very low, which is why oral trial doses run an order of magnitude above injectable ones.

By contrast, BPC-157 — a small unmodified peptide with no half-life-extending modification — has no published human pharmacokinetic data at all. The gap between the two illustrates what full clinical development actually produces.

Semaglutide Research Applications

• GLP-1R agonism mechanism research — the pure GLP-1R pathway, unconfounded by GIP or glucagon co-activation
• Glucose homeostasis — insulin secretion, glucagon suppression, glucose clamp models
• Gastric motility — GLP-1R effects on gastrointestinal transit
• CNS appetite research — hypothalamic and brainstem GLP-1 receptor distribution, appetite circuits
• Comparative incretin pharmacology — semaglutide as the mono-agonist baseline against tirzepatide (dual) and retatrutide (triple)
• Neuroprotection — GLP-1R signaling in neurodegeneration models
• Peptide engineering — albumin-binding half-life extension as a formulation strategy

All applications preclinical, in-vitro / in-vivo only.

Semaglutide Reconstitution & Storage

Supplied as a lyophilized powder. Reconstitute with bacteriostatic water, added slowly down the inside wall of the vial — never directly onto the powder. Swirl gently. Never shake, never vortex.

Storage: lyophilized and sealed, stable up to 24 months. Reconstituted, store at 2–8 °C and use within 30 days. Protect from light. Do not freeze after reconstitution.

Peptide Calculator · How to Reconstitute Peptides · Bacteriostatic water

Quality & Verification

Every CompoundPlug compound is tested independently through third-party laboratories, and the analysis is published rather than asserted.

This matters more for semaglutide than for almost anything else in the catalog. GLP-1 compounds are the most counterfeited category in the research-peptide market. Health Canada’s January 2026 advisory named the failure modes precisely: too much active ingredient, too little, or none at all — plus unlisted ingredients and contaminants.

HPLC for purity answers one of those questions: how much of this vial is semaglutide, and what else is in there.

Mass spectrometry for identity answers the other: is the compound in the vial actually semaglutide. A vial can be 99% pure and 99% the wrong molecule. Purity testing alone cannot catch that. Only mass spectrometry can.

Most vendors in this market publish one number. In the most counterfeited compound category that exists, one number is not enough.

Vials are measured by peptide content — the stated mass is peptide, not gross powder weight.

Where a batch has been independently re-tested under the CompoundPlug name, a CompoundPlug Verified badge appears alongside the batch-specific Certificate of Analysis, tied to the lot printed on the vial. Where it has not yet, the third-party source analysis is shown — testing laboratory named, manufacturer withheld.

Buy Semaglutide in Canada

Research-grade semaglutide — 10mg lyophilized powder, ≥99% HPLC purity, mass-spec verified for identity, with a published reference Certificate of Analysis tied to the lot on the vial.

• Semaglutide Canada-wide — ships from within Canada by Canada Post Xpresspost, tracked
• Semaglutide peptide Canada stock — every lot carries a published batch analysis
• CAD pricing
• Interac e-Transfer or cryptocurrency
• Discreet, unbranded packaging

Related: Semaglutide vs Tirzepatide — single agonist versus dual, with head-to-head trial data. Also in the catalog: tirzepatide, retatrutide, cagrilintide. Browse GLP-1 Peptides, or pick up bacteriostatic water.

Frequently Asked Questions